Jul. 17 at 6:33 PM
$GLMD
⸻
✅ Binding vs. Non‑Binding: What’s Going On?
🔹 Binding Term‑Sheet
The semaglutide licensing deal Galmed signed in late April 2025 with Entomus is indeed binding. Multiple sources confirm this, including press releases and financial news outlets:
• A PRNewswire release and outlets like TipRanks, GuruFocus, and MT Newswires all describe it as a binding term‑sheet, set to be finalized into a definitive agreement within 90 days  .
🔹 Non‑Binding Term‑Sheet
Separately — and likely the source of confusion — is a non‑binding term‑sheet referenced in older documents from 2023. That one was for a different initiative (related to OnKai) and was explicitly labeled as non‑binding .
⸻
📝 TL;DR
• The Entomus semaglutide agreement (April 2025) is binding.
• What’s non-binding is an older term‑sheet mentioned in 2023, unrelated to the current deal and part of a separate agreement.
⸻
